<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The endocannabinoid system is important in the pathogenesis of <z:hpo ids='HP_0001513'>obesity</z:hpo>-related <z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">metabolic disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, the effect of inhibiting the endocannabinoid system in type 2 diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> is unclear </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, we examined the effect of the cannabinoid (CB)1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, SR141716, on <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> in db/db mice </plain></SENT>
<SENT sid="3" pm="."><plain>Six-week-old db/db mice were treated with the CB1-specific <z:chebi fb="68" ids="48706">antagonist</z:chebi> SR141716 (10 mg/kg Â· d) for 3 months </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment with SR141716 significantly improved <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:chebi fb="23" ids="18059">lipid</z:chebi> abnormalities </plain></SENT>
<SENT sid="5" pm="."><plain>Concomitantly, CB1 antagonism improved cardiac functional and morphological abnormality, <z:hpo ids='HP_0001397'>hepatic steatosis</z:hpo>, and phenotypic changes of adipocytes into small differentiated forms, associated with increased adiponectin expression and decreased <z:chebi fb="23" ids="18059">lipid</z:chebi> <z:chebi fb="0" ids="35923">hydroperoxide</z:chebi> levels </plain></SENT>
<SENT sid="6" pm="."><plain>CB1 receptor was overexpressed in diabetic kidneys, especially in podocytes </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment with the SR141716 markedly decreased urinary albumin excretion and mesangial expansion and suppressed profibrotic and proinflammatory cytokine synthesis </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, SR141716 improved renal <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism and decreased urinary <z:chebi fb="0" ids="33023">8-isoprostane</z:chebi> levels, renal <z:chebi fb="23" ids="18059">lipid</z:chebi> <z:chebi fb="0" ids="35923">hydroperoxide</z:chebi> content, and renal <z:chebi fb="23" ids="18059">lipid</z:chebi> content </plain></SENT>
<SENT sid="9" pm="."><plain>In cultured podocytes, high-<z:chebi fb="105" ids="17234">glucose</z:chebi> stimulation increased CB1 receptor expression, and SR141716 treatment abolished high-<z:chebi fb="105" ids="17234">glucose</z:chebi>-induced up-regulation of collagen and plasminogen activator inhibitor-1 synthesis </plain></SENT>
<SENT sid="10" pm="."><plain>Additionally, knockdown of CB1 receptor expression by stealth small interfering <z:chebi fb="40" ids="33697">RNA</z:chebi> abolished high-<z:chebi fb="105" ids="17234">glucose</z:chebi>-induced <z:chebi fb="0" ids="15889">sterol</z:chebi>-regulatory element-binding protein-1 expression in podocytes </plain></SENT>
<SENT sid="11" pm="."><plain>These findings suggest that CB1 blockade improves <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and protect against renal injury through both metabolic and antifibrotic effects in type 2 diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Targeting CB1 blockade could therefore provide a new therapeutic target to prevent type 2 diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
</text></document>